Oxford Biomedica Company News



Company:
Epic Code:
ISIN No:
StockName:
Group:
Sector:
Sub Sector:
Country:
Region:
Market:
Market Cap:

OXFORD BIOMEDICA
OXB
GB0006648157
ORD GBP0.01
4577
Pharmaceuticals & Biotechnology
Pharmaceuticals
UK
Southeast
UK Main Market
60.6936153375 GBPm


Data as of 10:00 23/09/2009. Check director details and other company announcments at Oxford Biomedica Website .



RNS News for Oxford Biomedica





Regulatory News Service : RNS provides a service that enables local or international listed companies to meet company news reporting obligations in UK, Europe and US - international filings use different processes: Provides investors & professionals equal access to new company information as it is released. For further details of RNS news see London Stock Exchange website.



Latest Oxford Biomedica News



Running on Empty or is Oxford BioMedica PLC (OXB.L) Refueling?
Morgan Research - 21 hours ago
Shares of Oxford BioMedica PLC (OXB.L) have seen the needle move 0.23% or 0.02 in the most recent session. The LSE listed company saw a recent bid of 8.75 on 1340000 volume.

08/21/2017 02:52 PM


Oxford Biomedica Loss Narrows As It Progresses Novartis Collaboration
London South East (registration) (blog) - Aug 17, 2017
LONDON (Alliance News) - Oxford Biomedica PLC on Thursday reported a narrowed pretax loss for the first half of 2017, as it saw revenue improve, helped by its flagship collaboration with Novartis AG.

08/17/2017 10:22 AM


DIRECTOR DEALINGS: Oxford BioMedica Chief Business Officer Lifts Stake
London South East (registration) (blog) - Jul 17, 2017
LONDON (Alliance News) - Oxford BioMedica PLC said Chief Business Officer Peter Nolan bought 249,687 shares at a price of 8.01 pence per share Monday.

07/17/2017 01:14 PM


Oxford Biomedica extends contract with Swiss pharma giant Novartis
Proactive Investors UK - Jul 6, 2017
Oxford Biomedica (LON:OXB) saw its shares edge higher today on news it has extended its partnership with pharmaceutical giant Novartis, signing a new contract for the commercial and clinical supply of its LentiVector gene delivery technology.
Oxford Biomedica Signs 3-Year Commercial, Clinical Supply Agreement with Novartis - Fox Business
Oxford BioMedica wins big contract for Novartis cell therapy - Nasdaq

07/06/2017 08:48 AM


Small-cap focus: UK's booming biotech groups
Financial Times - Jun 23, 2017
Founded 20 years ago, Oxford BioMedica has grown rapidly in recent years, increasing staffing levels from 80 at the start of 2014 to 275 now, and investing £26m in the past two years in manufacturing facilities and laboratories.

06/23/2017 03:37 PM


Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review ...
Nasdaq - Jun 7, 2017
Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review ...

06/07/2017 02:18 PM